Sense Therapeutics utilizes CRISPR and other gene targeting tools to target genetic mutations in cancer. Different than the current immunotherapies which targeting tumor associated and tumor specific expressions on the cancer cell surfaces, the new method targets driver mutations intracellularly at nucleic acid level such as DNA, RNA.